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Clinics and pathology 
Disease 
Peripheral T-cell lymphoma, not otherwise specified 
(PTCL, NOS) 
Phenotype/cell stem origin 
Mature (peripheral) cytotoxic alpha-beta T-cell origin. 
Etiology 
No etiologic factors are known. 
Epidemiology 
Adult males (age range, 67-82 years). 
 
 
(A) Atypical lymphocytes in bone marrow smear from patient with PTCL, NOS with t(6;14)(p25.3;q11.2) (Wright-Giemsa, original 
magnification x1000). (B) Bone marrow trephine biopsy (H&E, x400). Tumor cells are (C) positive for CD2, (D) negative for CD5, (E) 
positive for granzyme B, and (F) positive for nuclear IRF4/MUM1 (x400). 
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Clinics 
Presentation with cytopenias in the absence of 
lymphadenopathy, sometimes with skin involvement. 
Pathology 
The bone marrow is hypercellular with the normal 
marrow elements replaced by an extensive infiltrate of 
atypical, mostly medium-sized lymphoid cells with 
irregular nuclear outlines. Admixed plasma cells and a 
background of reticulin fibrosis are present. The tumor 
cells display an abnormal T-cell phenotype with 
expression of CD3, the cytotoxic marker TIA1 (+/- 
granzyme B), and T-cell receptor-beta (beta-F1), but 
without coexpression of CD5. Most cases express CD4 
and lack expression of CD25 and CD30. IRF4/MUM1 
protein is expressed in tumor cell nuclei. Cases tested 
for EBV by in situ hybridization have been negative. 
Treatment 
No treatment data are available. 
Prognosis 





The rearrangement can be detected in standard G-
banded karyotype. 
Cytogenetics molecular 
The rearrangement can be detected using dual-fusion 
fluorescence in situ hybridization with probes to the 
IRF4 and TCR@ loci. 
Genes involved and proteins 
Note 
The IRF4/MUM1 protein is expressed in cases with 
t(6;14)(p25.3;q11.2). This expression likely results 






Nine-exon gene on 6p25.3. 
Protein 
The gene encodes interferon regulatory factor-4 
(IRF4)/multiple myeloma oncogene-1 (MUM1), a 
transcription factor in the IRF family. Its expression 






Other name: TRA@. 
DNA/RNA 
~ 1Mb on 14q11.2 containing TCR alpha V, J, and C 
regions, as well as the TCR-delta locus. 
Protein 
TRA@ encodes the T-cell receptor-alpha chains, 
translated from transcripts resulting from 
rearrangement of the TRAV and TRAJ regions and 
from TRAC. 




No RNA studies have been reported on cases with 
t(6;14)(p25.3;q11.2). Most translocations involving 




No studies of potential fusion proteins have been 
reported on cases with t(6;14)(p25.3;q11.2). Most 
translocations involving TRA@ in T-cell neoplasia do 
not produce fusion proteins. 
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